Open-Label Study to Assess Meplazumab in Adult Patients Diagnosed with Plasmodium Falciparum

Key facts

Sponsor

Jiangsu Pacific Meinuoke Bio Pharmaceutical Co Ltd

Intervention

Meplazumab for Injection(drug)

Enrollment

60 target

Eligibility

18-55 years · All sexes

Timeline

2024 – 2025

Study locations (1)

• Kisumu County Referral Hospital, Kisumu, Kenya

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Malaria

Additional recruiting or active studies for the same condition.

• RECRUITINGNANCT07257965
  Clinical Study to Assess Minimum Mosquito Bites for P. Vivax Infection in Thai Adults
  University of Oxford
• RECRUITINGPHASE2NCT07147400
  Pfs230D1 + R21 in Matrix-M1 in African School Children and Adults
  Serum Institute of India Pvt. Ltd.
• RECRUITINGPHASE2NCT07036159
  A Study to Assess the Safety and Immunogenicity of a Vaccine Against Malaria in Healthy Children Aged 5-60 Months
  GlaxoSmithKline
• ACTIVE NOT RECRUITINGPHASE1NCT06735209
  First-in-Human PfSPZ-LARC2 Vaccination/CHMI
  National Institute of Allergy and Infectious Diseases (NIAID)
• RECRUITINGPHASE2NCT07060508
  L9LS in Women of Childbearing Potential in Mali
  National Institute of Allergy and Infectious Diseases (NIAID)
• ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT06549257
  Assessing the Safety, Immunogenicity and Ex-vivo Efficacy of Two Candidate Malaria Transmission Blocking Vaccines, Pfs25-IMX313 and Pfs45/48 Administered Alone and in Combination, in Matrix-M Adjuvant
  University of Oxford
• ACTIVE NOT RECRUITINGNANCT06599593
  Leveraging the Seasonal Malaria Chemoprevention Platform to Address Malaria and Malnutrition
  University of California, San Francisco
• RECRUITINGPHASE4NCT07038837
  Comparison of Two Strategies for Administering the R21-Matrix M Vaccine in a Context of Seasonal Malaria Transmission in Chad
  Epicentre

See all trials for Malaria →